當(dāng)前位置：首頁 SCI期刊 SCIE期刊醫(yī)學(xué) 中科院3區(qū) JCRQ2 期刊介紹(非官網(wǎng))

Expert Opinion On Biological TherapySCIE

國(guó)際簡(jiǎn)稱：EXPERT OPIN BIOL TH 參考譯名：生物治療專家意見

中科院分區(qū)
3區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q2

基本信息：: ISSN：1471-2598; E-ISSN：1744-7682; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：ENGLAND; 出版商：Taylor and Francis Ltd.; 出版語言：English; 出版周期：Bimonthly; 出版年份：2001; 研究方向：生物工程與應(yīng)用微生物-醫(yī)學(xué)

評(píng)價(jià)信息：: 影響因子：3.6; H-index：75; CiteScore指數(shù)：8.6; SJR指數(shù)：1.104; SNIP指數(shù)：0.876

發(fā)文數(shù)據(jù)：: Gold OA文章占比：19.17%; 研究類文章占比：48.91%; 年發(fā)文量：92; 自引率：0; 開源占比：0.1394; 出版撤稿占比：0; 出版國(guó)人文章占比：0.03; OA被引用占比：0.0582...

投稿咨詢加急見刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡(jiǎn)介Expert Opinion On Biological Therapy期刊介紹

Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy.

Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.

The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease.

The journal welcomes:

Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine

Drug evaluations reviewing the clinical data on a particular biological agent

Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice

Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:

Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;

Article Highlights – an executive summary of the author’s most critical points.

期刊簡(jiǎn)介Expert Opinion On Biological Therapy期刊介紹

《Expert Opinion On Biological Therapy》自2001出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：一般,3-8周
醫(yī)學(xué)
BIOTECHNOLOGY & APPLIED MICROBIOLOGY
SCIE
中科院3區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Expert Opinion On Biological Therapy Cite Score數(shù)據(jù)

CiteScore：8.6
SJR：1.104
SNIP：0.876

學(xué)科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmacology	Q1	57 / 313	81%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Drug Discovery	Q1	32 / 157	79%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Clinical Biochemistry	Q1	26 / 117	77%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Expert Opinion On Biological Therapy 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：是 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	3區(qū)	BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程與應(yīng)用微生物 MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué)：研究與實(shí)驗(yàn)	2區(qū) 3區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Expert Opinion On Biological Therapy JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：BIOTECHNOLOGY & APPLIED MICROBIOLOGY	SCIE	Q2	59 / 174	66.4%
學(xué)科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q2	72 / 189	62.2%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：BIOTECHNOLOGY & APPLIED MICROBIOLOGY	SCIE	Q3	92 / 174	47.41%
學(xué)科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q3	98 / 189	48.41%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
USA142
Italy135
England57
GERMANY (FED REP GER)32
France28
Spain26
CHINA MAINLAND18
Netherlands15
Switzerland15
Japan14

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Recent advances in stem cell therapy for erectile dysfunction: a narrative review
Author: Wang, Bohan; Gao, Wenjun; Zheng, Micha Y.; Lin, Guiting; Lue, Tom F.

Journal: EXPERT OPINION ON BIOLOGICAL THERAPY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14712598.2023.2203811
2、Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group study
Author: Zhou, Wenjia; Wang, Meng; Yu, Yunli; Wang, Ji; Wu, Yanni; Yang, Guiyu; Yu, Haoyu; Li, Jing; Zhou, Liang; Zhang, Quanying

Journal: EXPERT OPINION ON BIOLOGICAL THERAPY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14712598.2023.2183117
3、Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial
Author: Guo, Yinhan; Guo, Tingting; Di, Yujing; Xu, Wenyu; Hu, Zhitian; Xiao, Yanfeng; Yu, Heze; Hou, Jie

Journal: EXPERT OPINION ON BIOLOGICAL THERAPY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14712598.2023.2178298
4、Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects
Author: Zhang, Qin; Sun, Cheng; Wu, Jinying; Wu, Juan; Zhang, Xuan; Liu, Yueyue; Dou, Changlin; Qin, Huilin; Zhang, Qian; Zhou, Renpeng; Hu, Wei

Journal: EXPERT OPINION ON BIOLOGICAL THERAPY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14712598.2023.2189009
5、Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis.
Author: Mok CC, Tsai WC, Chen DY, Wei JC.

Journal: Expert Opin Biol Ther. 2016;16(2):201-11. doi: 10.1517/14712598.2016.1118457. Epub 2015 Dec 2.
6、Fabrication of tissue-engineered vascular grafts with stem cells and stem cell-derived vascular cells.
Author: Wang L, Hu J, Sorek CE, Chen EY, Ma PX, Yang B.

Journal: Expert Opin Biol Ther. 2016;16(3):317-30. doi: 10.1517/14712598.2016.1118460. Epub 2015 Dec 8.
7、Recent considerations in the use of recombinant interferon gamma for biological therapy of atopic dermatitis.
Author: Brar K, Leung DY.

Journal: Expert Opin Biol Ther. 2016;16(4):507-14. doi: 10.1517/14712598.2016.1135898. Epub 2016 Mar 3.
8、Gene therapy strategies to improve strength and quality of flexor tendon healing.
Author: Tang JB, Zhou YL, Wu YF, Liu PY, Wang XT.

Journal: Expert Opin Biol Ther. 2016;16(3):291-301. doi: 10.1517/14712598.2016.1134479. Epub 2016 Feb 6.